HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Renal medullary carcinoma: case report and review of the literature.

Abstract
Renal medullary carcinoma is a recently recognized epithelial malignant tumor arising in the renal parenchyma. The tumor is almost exclusive to young black patients with the sickle cell trait. Most patients present with metastatic disease and have a poor prognosis. An Hispanic woman with renal medullary carcinoma who initially responded to chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin and survived for 12 months is presented. The clinical, histologic, and radiologic features of this tumor are described, and chemotherapeutic regimens used in this disease are detailed. Treatment modalities have proved largely unsuccessful in the setting of advanced disease. Given the shared demographic, clinical, and radiographic features of these patients, awareness and early diagnosis may prove essential in improving survival.
AuthorsWanda G Noguera-Irizarry, Hanina Hibshoosh, Kyriakos P Papadopoulos
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 26 Issue 5 Pg. 489-92 (Oct 2003) ISSN: 1537-453X [Electronic] United States
PMID14528077 (Publication Type: Case Reports, Journal Article, Review)
Chemical References
  • Vinblastine
  • Doxorubicin
  • Cisplatin
  • Methotrexate
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Carcinoma, Medullary (diagnosis, drug therapy, ethnology)
  • Cisplatin (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Fatal Outcome
  • Female
  • Hispanic or Latino
  • Humans
  • Kidney Neoplasms (diagnosis, drug therapy, ethnology)
  • Methotrexate (administration & dosage)
  • Vinblastine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: